|
|
|
Overviews
Low-Density Lipoprotein Apheresis in the Treatment of Atherosclerosis and Other Potential Uses
Moriarty PM, Gibson CA.
Curr Atheroscler Rep. 2001;3:156-162.
Effect of HELP-LDL-Apheresis on Outcomes in Patients With Advanced Coronary Atherosclerosis and Severe Hypercholesterolemia
Park J-W, Merz M, Braun P.
Atherosclerosis. 1998;139:401-409.
Long-Term Effect of Low-Density Lipoprotein Apheresis on Plasma Lipoproteins and Coronary Heart Disease in Native Vessels and Coronary Bypass in Severe Heterozygous Familial Hypercholesterolemia
Richter WO, Donner MG, Höfling B, Schwandt P.
Metabolism. 1998;47:863-868.
Abstracts
Long-Term Prevention of Premature Coronary Atherosclerosis in Homozygous Familial Hypercholesterolemia
Jaeger BR, Tsobanelis T, Bengel F, Schwaiger S, Seidel D.
J Pediatr. 2002;141:125-128.
This case study of a 22-year-old woman with homozygous familial hypercholesterolemia demonstrates the safety and efficacy of combined statins and LDL-apheresis using the heparin-induced method.
Click for full abstract.
Intravascular Ultrasound Evaluation of Coronary Plaque Regression by Low Density Lipoprotein-Apheresis Familial Hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART)
Matsuzaki M, Hiramori K, Imaizumi T, et al.
J Am Coll Cardiol. 2002;40:228-230.
This trial assessed the effects of LDL-apheresis for regression of coronary plaque in familial hypercholesterolemia using coronary angiography and intravascular ultrasound. The group that received medication and LDL-apheresis showed 28.4% reduction in total cholesterol, whereas the group that received medication showed no changes in cholesterol levels.
Click for full abstract.
Evidence for Maximal Treatment of Atherosclerosis: Drastic Reduction of Cholesterol and Fibrinogen Restores Vascular Homeostasis
Jaeger BR.
Ther Apher. 2001;5:207-211.
This article summarized the clinical and biochemical evidence for maximal treatment of atherosclerosis by a simultaneous 60% to 70% reduction of plasma LDL cholesterol, fibrinogen, and lipoprotein a (LPa) concentrations with statins and LDL-apheresis using the heparin-induced method. Potential future applications are also discussed.
Click for full abstract.
The Role of LDL Apheresis in Lipid Lowering Therapy for Hyperlipidemic Patients
Lane DM, Bricker LA, Schuff-Werner P.
Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drugs . 2000;2:216-222.
This review determines that the addition of LDL-apheresis to lipid-lowering drug therapy in hyperlipidemic patients can reduce pretreatment levels and produce lower between-treatment levels of LDL cholesterol than lipid-lowering drug therapy alone.
Full abstract not available.
Coronary Risk Factor Management for the Prevention and Treatment of Graft Vessel Disease in Heart Transplant Patients
Jaeger BR, Schirmer J, Thiery J, et al.
Ther Apher. 1999;3:214-218.
The authors studied whether heart transplant patients could benefit from a combined treatment of statins and LDL-apheresis using the heparin-induced method. Results suggest that early and drastic reduction of the main coronary risk factors may help to prevent retransplantation in high-risk patients.
Click for full abstract.
Therapeutic Effects of LDL Apheresis in the Prevention of Atherosclerosis
Kajinami K, Mabuchi H.
Curr Opin Lipidol. 1999;10:401-406.
The efficacy and safety of LDL-apheresis has already been established for lipid lowering in patients with refractory hypercholesterolemia. Two reports described excellent long-term follow-up results for patient with coronary artery disease who had been treated with LDL-apheresis using dextran sulfate cellulose columns plus lipid-lowering therapy.
Click for full abstract.
Long-term Efficacy of Low-Density Lipoprotein Apheresis on Coronary Heart Disease in Familial Hypercholesterolemia
Mabuchi H, Koizumi J, Shimizu M, et al, for the Hokuriku-FH-LDL-Apheresis Study Group.
Am J Cardiol. 1998;82:1489-1495.
This study describes the 6-year safety and efficacy of intensive cholesterol-lowering therapies with LDL-apheresis in heterozygous FH patients with CHD. Patients were treated with lipid-lowering drugs alone or with combined drug therapy and LDL-apheresis. Both treatment groups had significant reduction in cholesterol levels.
Click for full abstract.
Aggressive Lowering of Fibrinogen and Cholesterol in the Prevention of Graft Vessel Disease After Heart Transplantation
Jaeger BR, Meiser B, Nagel D, et al.
Circulation. 1997;96(suppl 9):II-157-II-158.
Combination therapy with statins and LDL-apheresis via the heparin-induced method is given to heart transplant patients to determine whether drastic lowering of fibrinogen, LDL-C, and Lp(a) prevent graft vessel disease (GVD). Results demonstrate that combined treatment prevents GVD in 9 of 10 patients.
Click for full abstract.
Additional Citations
Plasmalogen Phospholipids in Plasma Lipoproteins of Normolipidemic Donors and Patients With Hypercholesterolemia Treated by LDL Apheresis
Brautigam C, Engelmann B, Reiss D, et al.
Atherosclerosis. 1996;119:77-88.
Click for full abstract.
Changes in Plasma Lipid and Apolipoprotein Levels Between Heparin-Induced Extracorporeal Low-Density Lipoprotein Precipitation (HELP) Treatments
Lane DM, Alaupovic P, Knight-Gibson C, Dudley VS, Laughlin LO.
Am J Cardiol. 1995;75:1124-1129.
Click for full abstract.
Advances in LDL-Apheresis for the Treatment of Severe Hypercholesterolemia
Gordon BR, Saal SD.
Curr Opin Lipidol. 1994;5:69-73.
Click for full abstract.
Reverse Flux Filtration: A New Mode of Therapy Improving the Efficacy of Heparin-Induced Extracorporeal LDL Precipitation in Hyperlipidemic Hemodialysis Patients
Bosch T, Samtleben W, Thiery J, Gurland HJ, Seidel D.
Int J Artif Organs. 1993;16:75-85.
Click for full abstract.
Effect of Heparin-Induced Extracorporeal Low-Density Lipoprotein Precipitation and Bezafibrate on Hemorheology and Clinical Symptoms in Cerebral Multiinfarct Disease
Walzl M.
Haemostasis. 1993;23:192-202.
Click for full abstract.
Treatment of Severe Hypercholesterolemia With Heparin-Induced LDL-Apheresis
Richter WO, Jacob B, Ritter MM, Sühler K, Vierneisel K, Schwandt P.
Curr Ther Res. 1992;52:317-329.
Full abstract not available.
Combined LDL Apheresis and Hemodialysis in a Patient With End-Stage Renal Disease and Accelerated Coronary Atherosclerosis
Grutzmacher P, Vallbracht C, Scheuermann E, Kurz P, Schoeppe W.
ASAIO Trans. 1991;37:M435-M436.
Click for full abstract.
Extracorporeal Plasma Therapy in the Treatment of Severe Hyper-ß-Lipoproteinaemia: The HELP-System in Combination With HMG-CoA Inhibitors
Schuff-Werner P, Seidel D.
J Drug Dev. 1990;3:233-238.
Full abstract not available.
BACK TO TOP |
 |
 |
|